DK0950657T3 - Substituerede carbazoler, fremgangsmåde til deres fremstilling og deres anvendelse som sPLA2-inhibitorer - Google Patents

Substituerede carbazoler, fremgangsmåde til deres fremstilling og deres anvendelse som sPLA2-inhibitorer

Info

Publication number
DK0950657T3
DK0950657T3 DK99302967T DK99302967T DK0950657T3 DK 0950657 T3 DK0950657 T3 DK 0950657T3 DK 99302967 T DK99302967 T DK 99302967T DK 99302967 T DK99302967 T DK 99302967T DK 0950657 T3 DK0950657 T3 DK 0950657T3
Authority
DK
Denmark
Prior art keywords
preparation
spla2 inhibitors
substituted carbazoles
carbazoles
substituted
Prior art date
Application number
DK99302967T
Other languages
Danish (da)
English (en)
Inventor
Nicholas James Bach
Jolie Anne Bastian
Gary Alan Hite
Edward David Mihelich
John Michael Morin Jr
Daniel Jon Sall
Robert Theodore Vasileff
Michael Dean Kinnick
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0950657T3 publication Critical patent/DK0950657T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99302967T 1998-04-17 1999-04-16 Substituerede carbazoler, fremgangsmåde til deres fremstilling og deres anvendelse som sPLA2-inhibitorer DK0950657T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6232898A 1998-04-17 1998-04-17
EP99302967A EP0950657B1 (de) 1998-04-17 1999-04-16 Substituierte Karbazole, Verfahren zu ihrer Herstellung und ihre Verwendung als sPLA2-Inhibitoren

Publications (1)

Publication Number Publication Date
DK0950657T3 true DK0950657T3 (da) 2004-11-22

Family

ID=22041763

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99302967T DK0950657T3 (da) 1998-04-17 1999-04-16 Substituerede carbazoler, fremgangsmåde til deres fremstilling og deres anvendelse som sPLA2-inhibitorer

Country Status (30)

Country Link
EP (2) EP0950657B1 (de)
JP (2) JPH11322713A (de)
KR (2) KR19990083232A (de)
CN (1) CN1149193C (de)
AR (2) AR018593A1 (de)
AT (2) ATE271037T1 (de)
AU (2) AU753547B2 (de)
BR (2) BR9901279A (de)
CA (2) CA2269246C (de)
CO (2) CO5011054A1 (de)
CZ (2) CZ137099A3 (de)
DE (2) DE69918590T2 (de)
DK (1) DK0950657T3 (de)
DZ (1) DZ2769A1 (de)
EA (2) EA002347B1 (de)
ES (2) ES2222663T3 (de)
HU (2) HUP9901220A3 (de)
ID (2) ID23761A (de)
IL (2) IL129485A0 (de)
NO (2) NO314400B1 (de)
NZ (3) NZ507564A (de)
PE (2) PE20000432A1 (de)
PL (2) PL332566A1 (de)
PT (1) PT950657E (de)
SG (2) SG81977A1 (de)
SI (1) SI0950657T1 (de)
TR (2) TR199900853A2 (de)
TW (1) TWI238160B (de)
YU (2) YU19199A (de)
ZA (2) ZA992772B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1011670A4 (de) * 1997-08-28 2004-10-27 Lilly Co Eli Verfahren zur behandlung von nicht-rheumatischer arthritis
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
WO2000037022A2 (en) * 1998-12-21 2000-06-29 Eli Lilly And Company Combination therapy for the treatment of sepsis
JP2003505372A (ja) * 1999-07-19 2003-02-12 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビター
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
ES2294003T3 (es) * 2000-06-29 2008-04-01 Anthera Pharmaceuticals, Inc. Remedios contra el cancer.
US20040102442A1 (en) * 2000-06-29 2004-05-27 Kohji Hanasaki Remedies for alzheimer's disease
WO2002000256A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for cirrhosis
AU2001272915A1 (en) * 2000-07-14 2002-01-30 Eli Lilly And Company Method for treating sepsis
JP2004518659A (ja) 2000-12-18 2004-06-24 イーライ・リリー・アンド・カンパニー 新規ｓＰＬＡ２インヒビター
EP1395554B1 (de) 2001-03-28 2007-02-14 Eli Lilly And Company Substituierte carbazole als inhibitoren von spla2
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10249055A1 (de) 2002-10-22 2004-05-06 Bayer Cropscience Ag 2-Phenyl-2-substituierte-1,3-diketone
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP1988098A1 (de) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Neue Tetrahydrocarbazolderivate als Liganden von G-Protein-gekoppelten Rezeptoren
AU2009230127B2 (en) 2008-03-26 2011-12-22 Daiichi Sankyo Company, Limited Novel tetrahydroisoquinoline derivative
PE20091838A1 (es) 2008-04-09 2009-12-18 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de acido graso
EP2379538A4 (de) 2009-01-22 2013-01-02 Orchid Res Lab Ltd Heterozyklische verbindungen als phosophodiesterasehemmer
US8541581B2 (en) 2009-04-07 2013-09-24 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
ES2493916T3 (es) 2009-04-07 2014-09-12 Infinity Pharmaceuticals, Inc. Inhibidores de hidrolasa de amida de ácidos grasos
MX336742B (es) 2010-02-03 2016-01-29 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de acido graso.
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
BR112015012138A2 (pt) 2012-11-30 2017-07-11 Ge Healthcare Ltd composição, método para obtenção de uma composição, método de formação de imagem in vivo, e, kit
CA2889642A1 (en) 2012-11-30 2014-06-05 Ge Healthcare Limited Zinc halide mediated cyclization process leading to tricyclic indoles
EP3248230B1 (de) * 2015-01-20 2020-05-06 cynora GmbH Verwendung organischer moleküle in optoelektronischen bauelementen
CN108707104A (zh) * 2018-08-07 2018-10-26 北京恒信卓元科技有限公司 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579534A (en) * 1969-05-09 1971-05-18 American Cyanamid Co Tetrahydrocarbazolecarboxylates
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5472978A (en) * 1991-07-05 1995-12-05 Merck Sharp & Dohme Ltd. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
EP0749962B1 (de) * 1995-06-23 2000-11-02 Eli Lilly And Company 6-Subsitituierte-1,2,3,4-tetrahydro-9H-Carbazole und 7-substituierte-1OH-Cyclohepta(7,6-B)-Indole
KR19990072110A (ko) * 1995-12-13 1999-09-27 피터 지. 스트링거 Spla2 억제제인 나프틸 아세트아미드
BR9713261A (pt) * 1996-10-30 2000-03-28 Lilly Co Eli Tricìclicos substituìdos
WO1999016453A1 (en) * 1997-09-26 1999-04-08 Eli Lilly And Company Method for the treatment of cystic fibrosis
CA2310250A1 (en) * 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Also Published As

Publication number Publication date
NO991822L (no) 1999-10-18
KR19990083232A (ko) 1999-11-25
AU753547B2 (en) 2002-10-24
IL129483A0 (en) 2000-02-29
NO991822D0 (no) 1999-04-16
CA2269262A1 (en) 1999-10-17
CO5031247A1 (es) 2001-04-27
PE20000476A1 (es) 2000-06-02
AR018186A1 (es) 2001-10-31
PE20000432A1 (es) 2000-05-23
ES2222663T3 (es) 2005-02-01
EP0952149A2 (de) 1999-10-27
PL332565A1 (en) 1999-10-25
TR199900853A3 (tr) 1999-11-22
CZ137099A3 (cs) 1999-11-17
ATE271037T1 (de) 2004-07-15
HU9901221A (hu) 2000-04-28
NZ335251A (en) 2000-11-24
EA199900301A2 (ru) 1999-10-28
NZ335253A (en) 2000-11-24
KR19990083233A (ko) 1999-11-25
EA199900303A3 (ru) 2000-04-24
JP4435330B2 (ja) 2010-03-17
EA002816B1 (ru) 2002-10-31
DZ2769A1 (fr) 2003-12-01
BR9901279A (pt) 2000-05-02
KR100586761B1 (ko) 2006-06-08
HU9901221D0 (en) 1999-06-28
CA2269246C (en) 2009-08-25
HU9901220A (hu) 2000-04-28
YU18999A (sh) 2002-08-12
NO314400B1 (no) 2003-03-17
EP0952149B1 (de) 2004-06-09
AU753436B2 (en) 2002-10-17
DE69918590D1 (de) 2004-08-19
AU2381799A (en) 1999-10-28
EP0950657A2 (de) 1999-10-20
PT950657E (pt) 2004-11-30
SG81976A1 (en) 2001-07-24
TR199900843A2 (xx) 2000-02-21
NO991821L (no) 1999-10-18
TWI238160B (en) 2005-08-21
NO991821D0 (no) 1999-04-16
ID23287A (id) 2000-04-05
HUP9901220A3 (en) 2001-11-28
EA199900301A3 (ru) 2000-04-24
ZA992772B (en) 2002-07-16
BR9902365A (pt) 2001-04-24
ATE268756T1 (de) 2004-06-15
IL129485A0 (en) 2000-02-29
AR018593A1 (es) 2001-11-28
DE69918590T2 (de) 2005-07-21
ES2226286T3 (es) 2005-03-16
YU19199A (sh) 2002-08-12
SI0950657T1 (en) 2005-02-28
DE69917833D1 (de) 2004-07-15
CZ136999A3 (cs) 1999-11-17
PL332566A1 (en) 1999-10-25
ID23761A (id) 2000-05-11
CO5011054A1 (es) 2001-02-28
EP0950657A3 (de) 2001-08-16
EP0952149A3 (de) 2001-08-16
AU2381999A (en) 1999-10-28
HUP9901221A3 (en) 2001-11-28
CN1149193C (zh) 2004-05-12
JP2000026416A (ja) 2000-01-25
TR199900853A2 (xx) 1999-11-22
DE69917833T2 (de) 2005-07-14
CA2269246A1 (en) 1999-10-17
NZ507564A (en) 2002-10-25
HU9901220D0 (en) 1999-06-28
EP0950657B1 (de) 2004-07-14
EA199900303A2 (ru) 1999-10-28
JPH11322713A (ja) 1999-11-24
SG81977A1 (en) 2001-07-24
EA002347B1 (ru) 2002-04-25
ZA992771B (en) 2002-04-18
NO312240B1 (no) 2002-04-15
CN1253948A (zh) 2000-05-24

Similar Documents

Publication Publication Date Title
DK0950657T3 (da) Substituerede carbazoler, fremgangsmåde til deres fremstilling og deres anvendelse som sPLA2-inhibitorer
DK1076657T3 (da) Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
NO20012058D0 (no) 2-ureido-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
NO20032229L (no) Fremgangsmåter for behandling av p38kinase-assosierte tilstander og pyrrolotriazin forbindelser nyttige som kinase inhibitorer
DK1202733T3 (da) 3(5)-amino-pyrazolderivater, fremgangsmåde til deres fremstilling og deres anvendelse som antitumormidler
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
DK1133477T3 (da) Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
NO20011575L (no) Substituerte 3-cyanokinoliner som proteintyrosin-kinase- inhibitorer
NO20011574D0 (no) Substituerte 3-cyanokinoliner som proteintyrosin-kinsase- inhibitorer
NO20021239D0 (no) Pteridinoner som kinase-inhibitorer
DK1425014T3 (da) Diarylcycloalkylderivater, fremgangsmåde til deres fremstilling og deres anvendelse som PPAR-aktivatorer
NO20012158D0 (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
NO20015065D0 (no) Pyrazolobenzodiazepiner som CDK2-inhibitorer
NO20006029L (no) Pyrazolinderivater, deres fremstilling og anvendelse som legemidler
DK1330455T3 (da) Hidtil ukendte 7-azaindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
NO20015062D0 (no) Substituerte 3-cyano-[1.7],[1.5]og[1.8]-naftyridin- inhibitorer for tyrosin-kinaser
NO20034434D0 (no) Indolinoner substituert i 6-stilling og deres anvendelse som kinase-inhibitorer
NO20040210L (no) Fenylacetamido-tiazolderivater, fremgangsmate for deres fremstilling og deres anvendelse som antitumormidler
DK0795547T3 (da) (Aminoalkyl- og acylaminoalkyl-oxy)benzyloxyquinoliner, fremgangsmåde til deres fremstilling og deres anvendelse som bradyk
DK1068223T3 (da) Lipopeptidantibiotika-calciumsalte, fremgangsmåde til deres fremstilling og anvendelse
DK1098891T3 (da) Polycycliske thiazolidin-2-yliden-aminer, fremgangsmåde til fremstilling deraf og deres anvendelse som lægemidler
DK1214302T3 (da) Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-oner og deres anvendelse som lipasehæmmere
NO331195B1 (no) Fremgangsmate for fremstilling av halogen-substituerte monosulfider og deres hydroksymonosulfid-evkivalenter som mellomprodukter.
NO20013735L (no) Fremgangsmåte til fremstilling av di-iso-butaner, di-iso- butener og di-n-butener fra feltbutaner
NO20025884L (no) 2-aminotiazolinderivater og deres anvendelse som NO- syntaseinhibitorer